Contrasting of BioTime Inc. (BTX) and Novus Therapeutics Inc. (NASDAQ:NVUS)

BioTime Inc. (NYSEAMERICAN:BTX) and Novus Therapeutics Inc. (NASDAQ:NVUS), both competing one another are Biotechnology companies. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTime Inc. 4.99M 38.93 45.99M -0.58 0.00
Novus Therapeutics Inc. N/A 0.00 14.06M -1.37 0.00

Demonstrates BioTime Inc. and Novus Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 has BioTime Inc. and Novus Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioTime Inc. -921.64% -54.6% -51%
Novus Therapeutics Inc. 0.00% -55.5% -51.7%

Risk and Volatility

BioTime Inc.’s current beta is 3 and it happens to be 200.00% more volatile than S&P 500. Novus Therapeutics Inc.’s 257.00% more volatile than S&P 500 which is a result of the 3.57 beta.


The Current Ratio of BioTime Inc. is 8.2 while its Quick Ratio stands at 8.2. The Current Ratio of rival Novus Therapeutics Inc. is 10.7 and its Quick Ratio is has 10.7. Novus Therapeutics Inc. is better equipped to clear short and long-term obligations than BioTime Inc.

Institutional and Insider Ownership

BioTime Inc. and Novus Therapeutics Inc. has shares held by institutional investors as follows: 45.1% and 47.6%. BioTime Inc.’s share held by insiders are 0.8%. Comparatively, 0.8% are Novus Therapeutics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioTime Inc. -2.5% -17.02% -2.88% -40.61% -42.59% 28.15%
Novus Therapeutics Inc. -8% 6.98% 27.78% -8.37% 25.34% 187.5%

For the past year BioTime Inc.’s stock price has smaller growth than Novus Therapeutics Inc.


BioTime Inc. beats Novus Therapeutics Inc. on 5 of the 9 factors.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.